Luspatercept
- Generic Name
- Luspatercept
- Brand Names
- Reblozyl
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1373715-00-4
- Unique Ingredient Identifier
- AQK7UBA1LS
- Background
Luspatercept is a recombinant fusion protein comprised of a modified extracellular domain of activin receptor type IIB fused to the FC domain of human IgG1. It was first approved for use in the United States in November 2019 under the brand name Reblozyl® for the treatment of anemia in patients with beta thalassemia who require regular blood transfusions. Lu...
- Indication
Luspatercept is indicated for the treatment of:
- Associated Conditions
- Anemia
- Associated Therapies
- -
Extension Study to Evaluate the Safety and Efficacy of Luspatercept in Participants With β-Thalassemia Previously Enrolled in A536-04 (A536-06/MK-6143-004)
- First Posted Date
- 2014-10-20
- Last Posted Date
- 2024-07-18
- Target Recruit Count
- 51
- Registration Number
- NCT02268409
- Locations
- 🇮🇹
Acceleron Investigative Site, Turin, Italy
Extension Study to Evaluate Long-Term Effects of Luspatercept in Patients With Myelodysplastic Syndromes (MDS) (A536-05/MK-6143-003)
- First Posted Date
- 2014-10-20
- Last Posted Date
- 2024-07-29
- Target Recruit Count
- 75
- Registration Number
- NCT02268383
- Locations
- 🇩🇪
Acceleron Investigative Site, Dresden, Germany
Study of Luspatercept for the Treatment of Anemia in Patients With Myelodysplastic Syndrome (MDS) (MK-6143-001)
- First Posted Date
- 2012-12-13
- Last Posted Date
- 2024-07-29
- Target Recruit Count
- 116
- Registration Number
- NCT01749514
- Locations
- 🇩🇪
Acceleron Investigative Site, Dresden, Germany
Study to Evaluate the Safety and Efficacy of Luspatercept (ACE-536) in Participants With Beta-thalassemia (A536-04/MK-6143-002)
- First Posted Date
- 2012-12-13
- Last Posted Date
- 2024-07-18
- Target Recruit Count
- 64
- Registration Number
- NCT01749540
- Locations
- 🇮🇹
AORN A. Cardarelli, Napoli, Italy
🇮🇹CEMEF Medicina 2, Modena, Italy
🇮🇹ARNAS Garibaldi - P.O. Garibaldi Centro, Catania, Italy
Connect® Myeloid Disease Registry
- Conditions
- Interventions
- First Posted Date
- 2012-09-19
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- Celgene
- Target Recruit Count
- 2300
- Registration Number
- NCT01688011
- Locations
- 🇺🇸
Local Institution - 1088, Cleveland, Ohio, United States
🇺🇸Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States
🇺🇸TriHealth, Good Samaritan Hospital, Cincinnati, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.